Artificial Intelligence and LLMs in Regulatory Affairs

Regulatory affairs (RA) professionals ensure that products and services comply with laws, standards, and regulations to protect public and financial interests. Traditionally, RA is most prominent in health-related fields: pharmaceuticals, biotechnology, and medical devices, where agencies like the FDA (USA) or EMA (EU) require rigorous approval processes. For example, in pharmaceuticals, RA specialists manage new-drug approvals, safety monitoring, and clinical trial compliance ^{[1] [2]}. In the medical device industry, a dedicated framework (e.g. the EU’s MDR) ensures patient safety; the RA department identifies applicable standards, interprets requirements for internal stakeholders, and guides product approvals ^[3] journals.aboutscience.eu. Figure: A laboratory setting highlighting the importance of medical device regulation. Regulatory affairs in this sector “aim to protect the patient and ensure health benefits” by enforcing safety and efficacy standards ^[3].

Beyond healthcare, RA functions exist wherever regulation safeguards interests. For instance, finance and banking have extensive compliance units: they enforce rules on banking operations, investments, insurance, audits, and anti-money-laundering (AML) practices ^{[4] [5]}. Other regulated sectors include food and beverages (food safety, labeling), environment and natural resources (pollution control, emissions, sustainability), technology and telecommunications (data privacy, cybersecurity, telecom licensing) ^{[6] [7]}. In fact, one industry analysis notes that RA roles are “particularly prominent” not only in pharmaceuticals and agrochemicals but also in telecoms, cosmetics, finance, and any field where regulators protect public interests ^{[7] [6]}. In each sector, RA teams monitor legislation, advise management on requirements, prepare and review compliance documentation, and liaise with authorities ^[7]. These multidisciplinary efforts ensure that products and services meet regulatory criteria throughout their lifecycle ^{[2] [3]}.

• Pharmaceuticals/Biotech: Drug approval dossiers, pharmacovigilance, quality assurance (cGMP) – RA coordinates submissions to FDA/EMA and monitors safety.

• Medical Devices: Documentation for CE/510(k) approvals, clinical evaluation reports, post-market surveillance – RA ensures compliance with device-specific regulations ^[3] journals.aboutscience.eu.

• Finance/Banking: Compliance programs for AML/BSA, SEC/FINRA rules, audit readiness – RA/compliance teams translate laws into internal policies and reporting systems.

• Food & Environment: Safety certificates, labeling compliance, emissions reporting – RA units implement standards (e.g. FDA food codes, environmental statutes) and maintain records.

• Tech & Telecom: Data protection policies (e.g. GDPR), cybersecurity standards, licensing regulations – RA ensures products and communications comply with recent tech laws ^{[8] [7]}.

Each of these fields shares the goal of protecting consumers or the public. RA professionals must stay abreast of evolving standards (e.g. new EU medical regulations, changing banking laws) and translate them into company practices ^{[7] [6]}. The regulatory landscape is global and fragmented: different countries and agencies may have distinct or conflicting requirements, creating complexity for multinational companies.

Managing regulatory compliance has long been cumbersome. Life sciences companies, for example, juggle vast volumes of complex documents: submission dossiers, trial reports, quality manuals, and more. These documents are frequently updated, leading to version-control issues. One regulatory tech analysis notes that “complex document revisions” with frequent updates can cause non-compliance risks if version control fails ^[9]. Similarly, having multiple product lines (and thus multiple portfolios of regulations) often results in scattered, disorganized storage. As one industry report puts it, “ fragmented document storage” and “manual workflows” amid ever-evolving global standards can lead to delays, non-compliance, and even financial penalties ^[9].

The human factor adds further difficulties. Regulatory content must be consistent and error-free: any oversight in a submission can delay approvals or trigger audits. For instance, inconsistencies across documents can cause misinterpretation; incomplete records can “jeopardize the validity” of a study roboreg.ca. Ensuring audit readiness at any time demands meticulous organization and frequent checks. Additionally, large-scale regulatory programs involve coordination across departments, often across languages and regions, which increases overhead. In short, firms face:

• Rapidly Changing Rules: Regulations are constantly evolving (e.g. yearly guideline updates). Keeping up is “daunting,” and failure to use the latest standards can lead to rejections of submissions roboreg.ca.

• Volume and Version Control: Hundreds or thousands of pages of regulation and company documents, with frequent revisions, create a version-control nightmare ^[9].

• Manual Processes: Much of RA work (document reviews, ga Computer System Validation (CSV) is, its crucial role in pharmaceutical and biotech compliance, ensuring data integrity and regulatory adherence for patient safety.p analyses, audit prep) has traditionally been manual, time-consuming, and error-prone ^[9] roboreg.ca.

• Data Integrity & Security: Protecting sensitive regulatory data (clinical results, trade secrets) is critical. Large unstructured datasets are susceptible to errors or breaches if not carefully managed (as regulatory oversight becomes increasingly digital, security is a greater concern ^[10]).

• Global Coordination: Multilingual requirements and divergent jurisdictional rules add complexity (e.g. labeling in local language, dual-language approvals, differing national guidelines).

Together, these challenges make RA resource-intensive. Companies invest heavily in compliance teams and systems to avoid costly non-compliance issues.

Artificial intelligence (AI), especially generative AI and large language models (LLMs), promises to alleviate many RA burdens. By automating language-intensive tasks, AI can reduce manual workload, improve accuracy, and accelerate response to regulatory changes. Leading consulting analyses highlight that generative AI can transform regulatory workflows in three key ways ^[11]:

• Understanding Regulations: LLMs can parse and summarize complex regulatory texts. Users can “ask questions and receive answers grounded in facts” about dense documents, focusing on relevant sections ^[12]. For example, instead of manually sifting a guideline, a compliance officer could query an AI: “What are the FDA’s requirements for data submission in clinical trials?” The AI would scan the guidance and extract the answer, even comparing multiple country regulations and synthesizing the result ^[12]. This makes exploring lengthy rules or comparing international requirements far faster than manual review.

• Compliance Gap Analysis: AI can compare current company documents (policies, SOPs) against new or updated regulations. By highlighting discrepancies, the model accelerates “gap assessments and compliance analyses” ^[13]. For instance, after a new data protection regulation is released, an LLM may help reviewers identify potentially outdated statements in a firm’s privacy policy. Qualified compliance and legal reviewers must assess the source regulation, the identified gaps, and any proposed remediation before action is taken.

• Document Generation and Updates: Once differences are identified, AI can draft or update policies, standard operating procedures, and submission documents accordingly. Generative models can create first-draft sections of regulatory submissions, labeling documents, or training materials ^[14]. For example, Merck’s pharmaceutical division uses an internal AI tool to generate first drafts of regulatory documents for health authority submissions; these drafts are then reviewed and edited by experts ^[15]. This greatly reduces the rote writing burden on highly specialized scientists. AI can also help train personnel on new requirements via Q&A chat interfaces or by generating questionnaires (as tested in a medical-device use case) ^[16].

• Regulatory Intelligence and Alerts: Beyond static tasks, AI can monitor public sources. LLMs can continuously scan and flag regulatory news or guideline updates from agencies (FDA, EMA, MFDS, etc.), alerting RA teams in real time. In a proof-of-concept study, AI was tasked with answering queries from a repository of 100 global guidance documents. The LLM delivered accurate responses about regulatory criteria in ~77% of cases, demonstrating its promise to speed up information gathering in RA ^[17]. In January 2026, the FDA and EMA published ten joint guiding principles for good AI practice in drug development. The principles call for scheduled monitoring and periodic re-evaluation of AI models, including evaluation for data drift; they are guidance rather than mandatory requirements ema.europa.eu.

• Multilingual Compliance Support: Modern LLMs can help prepare translation and localization drafts for regulatory content. They do not establish that legal or regulatory meaning has been preserved. Each jurisdiction-specific draft requires review by appropriately qualified regulatory, legal, and translation professionals before use or submission.

• Predictive Analytics: Models may be evaluated for narrowly defined forecasting tasks using relevant historical data. Forecasts should be treated as decision support rather than predictions of regulator decisions, and their performance must be validated for the specific context of use before they inform regulated work.

In summary, AI-powered tools offer improved efficiency, consistency, and insight in RA. By handling repetitive text analysis and creation tasks, they free professionals to focus on higher-level strategy. These capabilities make AI particularly well-suited for regulatory domains that are heavily text-based and rules-driven.

Large language models (LLMs) such as OpenAI's ChatGPT and Google's Gemini are at the forefront of generative AI applications. They excel at understanding and generating human-like text, which directly maps to many RA tasks:

• Text Generation: LLMs can draft high-quality language for submissions, reports, and communications. For example, companies are using ChatGPT to write draft sections of regulatory submissions, standard operating procedures, and compliance reports ^{[14] [15]}. ChatGPT’s ability to produce coherent, structured text means it can output initial versions of documents (e.g. risk analyses, labeling text) that humans then refine. Similarly, Google’s Gemini can compose content and even code snippets if needed for internal tools.

• Summarization and Q&A: LLMs can compress long documents into concise summaries or answer specific questions about them. In a healthcare regulatory context, a LLM was able to parse health authority guidance and provide answers to targeted queries, greatly reducing research time ^{[18] [17]}. This is valuable for literature reviews or drafting executive summaries of technical files. ChatGPT’s chat interface also allows interactive exploration: an RA expert can iteratively probe regulations by refining their prompts.

• Compliance Analysis: LLMs can assist reviewers by extracting candidate obligations, comparing text against approved materials, and flagging possible inconsistencies. Qualified reviewers must verify the applicable requirements, evidence, and any resulting changes; model output is not itself a compliance determination.

• Multilingual Support: LLMs can help prepare translation drafts and support cross-lingual research. They cannot establish that a translation preserves legal or regulatory meaning, and grounded retrieval does not substitute for validated legal research. Appropriately qualified regulatory, legal, and translation professionals must review each jurisdiction-specific document before it is used or submitted.

• Knowledge Integration: Some LLMs can be connected to enterprise knowledge bases. For example, ChatGPT’s enterprise offerings allow uploading of internal documents. This means a company can build an AI assistant with access to its proprietary dossiers, policies, and historical submissions. Queries then yield answers grounded in both open regulations and the company’s own files.

• Automated Reasoning: Modern LLMs can help produce draft decision trees for compliance processes or draft test cases for system validation. Qualified reviewers must verify the underlying requirements, logic, and final output before use.

While promising, these models have limitations. They may hallucinate (generate incorrect statements) or lack domain-specific knowledge. To mitigate this, companies are developing domain-specific LLMs. For example, Writer has released Palmyra-Med (a 70B-parameter LLM) trained on medical corpora, and Palmyra-Fin for finance. Palmyra-Med averages 85.9% accuracy across medical benchmarks, surpassing Med-PaLM-2 and even outperforming human test-takers on PubMedQA (81.1% vs. 78.0%) ^{[19] [20]}. Palmyra-Fin notably scored 73% on the CFA Level III exam, becoming the first model to pass this prestigious investment certification ^[19]. By fine-tuning on sector-specific data, these models achieve higher accuracy and reliability for RA tasks (e.g. pharmacovigilance queries or regulatory compliance standards). Using such tailored LLMs can reduce errors in specialized content generation and improve compliance with domain norms, while costing substantially less than frontier models—Palmyra-Med is priced at $10 per million output tokens compared to $60 for GPT-4 ^[20].

In practice, organizations often compare multiple LLMs for their needs. OpenAI's GPT-5 (released August 2025) offers expanded agentic capabilities, enabling it to act as an enterprise agent rather than just a chatbot—automating SOPs, training modules, and compliance monitoring ^[21]. GPT-5 does not support fine-tuning. For recurring compliance language or required criteria, teams can use carefully designed prompts, retrieval from approved source materials, structured outputs, and output-validation checks, with qualified human review. Google documents Gemini 3.1 Pro as a preview model with text, image, video, audio, and PDF inputs, as well as optional Search grounding. Whether a deployment is suitable for regulated data depends on the specific Google service, configuration, and contractual terms; a model itself should not be described as HIPAA-ready or as holding organization- or service-level certifications. Google's Cloud BAA lists the covered services and products for HIPAA workloads. Anthropic's Claude and Meta's LLaMA models are also used in some organizations (Merck's GPTeal platform supports both LLaMA and Claude under the hood ^[22]), each with their own trade-offs in creativity vs. conservatism. The key is that a mix of LLMs – generalists, specialists, and open-weight models where their licence and deployment requirements are suitable – may be applied to different parts of the RA workflow.

Model	Strengths	Limitations
OpenAI GPT-5 (August 2025)	Reasoning and agentic capabilities for enterprise automation; can be used with approved retrieval, structured outputs, and validation checks for compliance workflows.	Does not support fine-tuning; requires robust governance for enterprise deployment and qualified review of outputs.
OpenAI GPT-5.2 (previous frontier model)	Configurable reasoning effort, structured outputs, and text and image inputs.	OpenAI identifies GPT-5.2 as a previous frontier model and recommends its latest model for new work; validate outputs and select the model at deployment time. OpenAI documentation
Google Gemini 3.1 Pro Preview	Supports text, image, video, audio, and PDF inputs, plus optional Search grounding.	It is a preview model; pricing and availability can change. Compliance obligations depend on the selected service, configuration, and contractual terms rather than on a model-level certification.
Specialized LLMs (Palmyra-Med/Fin)	Palmyra-Med: 85.9% on medical benchmarks, outperforms humans on PubMedQA; Palmyra-Fin: first to pass CFA Level III (73%); 6x cheaper than GPT-4 (now deprecated) [19].	Fewer parameters than frontier models; not recommended for direct patient care; requires qualified oversight.
Anthropic Claude	Anthropic is listed by the European Commission as a signatory to the voluntary General-Purpose AI Code of Practice.	Do not make a general capability ranking without naming the Claude version, benchmark, test conditions, and reproducible results; evaluate the selected model for the intended task.
Open-weight models (Llama 3, etc.)	Can be customized and deployed in an organization's own environment, subject to the applicable licence and infrastructure requirements.	Require in-house expertise to fine-tune and secure; Llama 3 is distributed under Meta's Community License, which includes use and commercial restrictions.

For regulatory tasks, accuracy and trustworthiness are paramount. Model selection should be based on documented, task-specific evaluation, approved data access, output controls, and qualified human review; product choices should be reassessed as models and service terms change. Enterprises often wrap these in governance layers: for instance, Merck’s “GPTeal” platform lets employees query ChatGPT, LLaMA or Claude securely with enterprise controls ^[22]. This way, Merck leverages the best of each while tracking usage and protecting data.

Pharmaceutical and Biotech: Major pharma companies have moved beyond pilots to enterprise-wide AI deployment. In June 2025, Merck publicly described an internal generative-AI platform for drafting clinical study reports (CSRs). Across multiple studies, Merck reported reducing the average time to create a fully human-reviewed first draft from 180 to 80 hours and reducing specified drafting errors by 50% ^[23]. Similarly, Pfizer has rolled out its generative AI platform "Charlie" (named after co-founder Charles Pfizer) to thousands of marketing employees and agency partners. Charlie can fact-check, perform legal reviews, and create compliant content with a color-coded risk system (red/yellow/green) to alert staff when human review is needed ^[24]. Pfizer's AI-powered predictive machine learning research hub can now identify promising drug candidates in 30 days or less, compared to months or years using traditional methods ^[25]. Startups and CROs continue to offer AI tools to automatically tag and summarize dossiers, or to generate clinical study reports with AI assistance (often under human supervision).

Medical Devices: A recent academic study tested ChatGPT on a simulated device registration process. Researchers prompted the LLM with aspects of the EU MDR requirements (2017/745) and asked it to perform tasks like creating checklists or translating regs into plain language. They found ChatGPT could produce reasonably structured outputs, but required precise prompt engineering. The conclusion emphasized that ChatGPT “represents a powerful tool to support decision-making” in device RA, improving efficiency when users apply strategic prompting and review journals.aboutscience.eu. The study suggests that in practical device trials, AI could help formulate technical documentation and survey questions, but experts must guide and validate the outputs.

Financial Services: Banks and financial institutions are exploring LLMs for compliance. IBM notes that LLMs (e.g. GPT-4) have been evaluated for anti-money-laundering (AML) compliance: they can automate transaction monitoring, flag suspicious patterns, and assist investigators ^[5]. For example, an LLM could parse customer transaction records and compliance guidelines to highlight unusual behavior, or suggest audit follow-ups. Pilot projects at large banks (like JPMorgan Chase) have used generative AI to draft compliance reports or analyze regulatory filings. These applications promise “driving compliance and efficiency” by automating rule checks and anomaly detection ^[5].

Global Regulatory Intelligence: Several initiatives use LLMs to handle international compliance data. One project ingested 100 guidelines from various health authorities into an AI system. When regulatory professionals asked the LLM questions (e.g. FDA’s stance on AI in manufacturing), about 77% of responses were accurate or nearly so compared to source documents ^[17]. This suggests LLMs can aggregate and answer queries across multiple regulatory sources much faster than manual research. Companies are beginning to deploy chatbots trained on their regional regulators’ documents to answer employee queries about upcoming rule changes, submission requirements, or labeling criteria. These AI assistants serve as a rapid Q&A for RA teams.

Other Sectors: While less documented in open sources, similar pilots occur in telecoms (AI helps interpret new spectrum regulations), energy (LLMs draft environmental compliance reports), and food (AI summarizes FDA food safety updates). The common theme is using AI to reduce routine research and writing.

In all these cases, AI does not replace experts but augments them: it handles tedious analysis so professionals focus on judgment and strategy. Early adopters report significant time savings – for example, Deloitte estimates that AI could eliminate many hours of manual regulation review ^[11] – and faster turnaround on submissions and audits.

Introducing AI into regulatory workflows brings new risks that must be managed carefully. Since regulatory content is sensitive, errors can have serious consequences. Key considerations include:

• Output Accuracy and Hallucinations: LLMs can sometimes generate plausible-sounding but incorrect or fabricated information. In a regulatory context, a hallucinated rule or misinterpreted guideline could mislead compliance efforts. Therefore, all AI-generated content must be reviewed by qualified professionals. As one study on medical-device RA notes, maximizing AI’s benefits “requires continuous training, prompt optimization, and adaptation,” meaning users must be adept at shaping AI outputs and critically evaluating them journals.aboutscience.eu. Companies should adopt a “human-in-the-loop” approach, verifying every AI draft against source documents and regulations.

• Data Privacy and Security: RA teams handle proprietary and confidential data (clinical trial results, formula details). Feeding this information into a cloud-based LLM can risk leaks. For example, one corporate CIO highlighted that unprotected use of ChatGPT could inadvertently expose IP or patient information ^[26]. To mitigate this, organizations implement secure access (e.g. Merck's GPTeal, which isolates queries in a private environment) and data anonymization. Industry best practices call for encryption, strict access controls, and compliance with data protection laws (e.g. HIPAA, GDPR) when using AI tools. In healthcare RA, LLMs could potentially reveal personal data, so anonymization and secure data handling are mandatory. Modern enterprise AI platforms now support regional data residency, private routing, and custom retention windows for stricter compliance alignment ^[27].

• Regulatory Oversight: The FDA issued draft guidance in January 2025: "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products." The document is marked "Not for implementation" and contains non-binding recommendations. It sets out a seven-step risk-based credibility assessment framework that may be used to establish and evaluate an AI model’s credibility for a particular context of use: (1) define the question of interest, (2) define the context of use, (3) assess model risk, (4) develop a credibility plan, (5) execute the plan, (6) document the results of the credibility-assessment plan and discuss deviations from the plan, and (7) determine the AI model’s adequacy for its context of use ^[28]. The guidance was informed by more than 500 AI-related drug and biological product submissions since 2016. In May 2025, the FDA announced completion of an AI-assisted scientific-review pilot and its plan for an agency-wide rollout. It launched its internal generative-AI tool, Elsa, on June 2, 2025. In January 2026, the FDA and EMA jointly released "Guiding Principles of Good AI Practice in Drug Development," establishing ten common principles across both regulatory systems ema.europa.eu. The EU AI Act has a phased timetable. Prohibitions, definitions, and AI-literacy provisions applied from February 2, 2025; governance and general-purpose AI-model obligations applied from August 2, 2025; and transparency requirements and enforcement began on August 2, 2026. The rules for high-risk systems in Annex III apply from December 2, 2027, while rules for high-risk AI embedded in regulated products apply from August 2, 2028. Commission materials describe the July 2026 Article 4 amendment differently: the Commission’s AI-literacy Q&A says providers and deployers still have an AI-literacy obligation, without a prescribed “sufficient” level, while the AI Act Service Desk describes the change as shifting responsibility toward Commission and Member State promotion rather than unspecified operator obligations. The high-risk deployer training requirement remains. Organisations should determine their obligations from the applicable consolidated legal text and, where material, obtain legal advice rather than treating either explanatory page as a substitute for it. European Commission AI-literacy Q&A AI Act Service Desk FAQ

• Ethical and Bias Concerns: AI models reflect their training data. If an LLM is trained mostly on English-language or Western-sourced documents, it might underrepresent perspectives or regulations from other regions, inadvertently biasing compliance advice. Enterprises must ensure that AI tools cover all relevant jurisdictions and that biases are checked. Deloitte emphasizes that deploying generative AI ethically requires "robust governance frameworks and ongoing monitoring" to detect bias and ensure fairness ^[29]. This includes setting up review boards, auditing AI outputs regularly, and updating models as laws change. The European Commission lists Amazon, Anthropic, Google, IBM, Microsoft, and OpenAI among the signatories to the voluntary General-Purpose AI Code of Practice. The Commission updates that list as signatures are confirmed.

• Intellectual Property and Authenticity: Regulatory submissions often require original analyses. Relying too heavily on AI-generation could raise questions about authorship or inadvertent plagiarism of copyrighted training data. Companies should ensure that any AI use complies with copyright and that proprietary data used to train models is cleared for use.

• Change Management: Finally, there is human risk. Staff must be trained in new AI-augmented workflows. An internal study suggests running pilot tests on subsets of documents and validating accuracy before full rollout roboreg.ca. Clear policies (“AI usage guidelines”) should define what tasks are allowed (e.g. use ChatGPT only for first drafts, never for final content) and how to cite AI contributions if needed. The Merck GPTeal case underscores this: by formally implementing an internal AI tool and educating employees, Merck enabled wide AI adoption while controlling risk ^[22]. Such governance ensures that AI “assists” compliance without undermining quality or accountability.

In sum, AI in RA must be approached as subject to continuous validation. Every automated output is ultimately the sponsor’s responsibility. With rigorous oversight – validation studies, privacy safeguards, and human review – organizations can leverage AI’s power while maintaining regulatory trust.

The impact of AI on regulatory affairs has accelerated dramatically in 2025-2026, with regulatory agencies themselves now actively deploying AI internally. The FDA launched "Elsa," its internal generative AI tool, in June 2025, built within a high-security GovCloud environment to expedite clinical protocol reviews and identify high-priority inspection targets. The FDA also appointed a Chief AI Officer to coordinate implementation across all centers ^[30]. The European Medicines Agency (EMA) and the wider European medicines regulatory network are implementing a 2025–2028 AI workplan covering guidance, tools and technology, collaboration and change management, and experimentation. EMA’s public materials report that its AI-enabled Scientific Explorer was extended in March 2026 to support searches related to initial marketing-authorisation applications. The joint FDA-EMA principles released in January 2026 provide ten guiding principles for AI use across medicine development. They include scheduled monitoring and periodic re-evaluation, including for data drift, but do not create binding requirements ema.europa.eu.

The EU AI Act is a binding legal framework with phased application. Its high-risk-system rules in Annex III apply from December 2, 2027, and its rules for high-risk AI embedded in regulated products apply from August 2, 2028. European Commission AI Omnibus update

Moreover, as AI lowers barriers to entry, even smaller companies and startups are gaining access to sophisticated RA support. Domain-specific models like Palmyra-Med offer frontier-level performance at a fraction of the cost. The cumulative effect is a faster, more data-driven global regulatory system where human experts focus on strategic oversight while AI handles routine analysis. Finland became the first EU member state with full AI Act enforcement powers in December 2025, signaling that compliance enforcement is now operational ^[31].

In conclusion, AI and LLMs have transformed regulatory affairs beyond early adoption into enterprise-wide deployment. Companies like Merck and Pfizer report dramatic efficiency gains—clinical study report drafting reduced from weeks to days, drug candidate identification from years to 30 days. The regulatory landscape has matured significantly: the FDA's January 2025 guidance, the joint FDA-EMA principles of January 2026, and the EU AI Act's phased implementation, including later deadlines for high-risk systems, provide clear frameworks for responsible AI use ^[28] ema.europa.eu. Domain-specific models may be evaluated for particular regulatory tasks, but published benchmark scores and token prices alone do not establish suitability or superiority for a regulated workflow. Careful governance remains essential to manage risks, but with robust validation, privacy safeguards, and human oversight, AI is helping regulators and industry alike keep pace with innovation and safeguard public health and safety. The long-term outlook is continued experimentation with AI-assisted regulatory workflows, with outcomes depending on context-specific validation, governance, and qualified human oversight.

Sources: This report synthesizes industry analyses, official guidelines, and case studies on AI in regulatory compliance ^{[9] [12] [17] [15]} ema.europa.eu. Source authority varies; readers should rely on the linked primary regulator and official company sources for regulatory requirements and product-specific claims.